Skip to main content
GutCited
Figure 3. The immuno-suppressive and immuno-resolving approaches of inflammatory bowel disease treatment. AZA, azathioprine; PUFA, polyunsaturated fatty acid; TNF, tumour necrosis factor.
Figure 7. Figure 3. The immuno-suppressive and immuno-resolving approaches of inflammatory bowel disease treatment. AZA, azathioprine; PUFA, polyunsaturated fatty acid; TNF, tumour necrosis factor.

Description

Current IBD treatments employ both immuno-suppressive and immuno-resolving strategies. This diagram contrasts conventional therapies (azathioprine, anti-TNF agents) with emerging PUFA-based approaches that promote active resolution of intestinal inflammation.

More Figures from This Paper

N-3 and n-6 polyunsaturated fatty acids follow distinct biosynthetic pathways to produce eicosanoids and specialized pro-resolving mediators. This diagram outlines the synthesis routes from alpha-linolenic acid and arachidonic acid through COX and cytochrome P450 enzymes to their bioactive lipid products.

Figure 5

N-3 and n-6 polyunsaturated fatty acids follow distinct biosynthetic pathways to produce eicosanoids and specialized pro-resolving mediators. This diagram outlines the synthesis routes from alpha-linolenic acid and arachidonic acid through COX and cytochrome P450 enzymes to their bioactive lipid products.

diagram
N-3 polyunsaturated fatty acids modulate intestinal innate immunity through multiple receptor and signaling targets. This diagram maps the interactions of DHA and EPA with G-protein coupled receptors, COX enzymes, and caspase recognition domains in intestinal immune cells.

Figure 6

N-3 polyunsaturated fatty acids modulate intestinal innate immunity through multiple receptor and signaling targets. This diagram maps the interactions of DHA and EPA with G-protein coupled receptors, COX enzymes, and caspase recognition domains in intestinal immune cells.

diagram

Figure 7

Diagram
463 × 291px · 52.3 KB

Source Paper

The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel Disease: A Comprehensive Review and Future Therapeutic Perspectives.

International journal of molecular sciences (2017)

PMID: 29206211

DOI: 10.3390/ijms18122619

Cite This Figure

![Figure 7: Current IBD treatments employ both immuno-suppressive and immuno-resolving strategies. This diagram contrasts conventional therapies (azathioprine, anti-TNF agents) with emerging PUFA-based approaches that promote active resolution of intestinal inflammation.](https://pdfs.citedhealth.com/figures/29206211/413.png)

> Source: Eleonora Scaioli et al. "The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel." *International journal of molecular sciences*, 2017. PMID: [29206211](https://pubmed.ncbi.nlm.nih.gov/29206211/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/29206211/413.png" alt="Current IBD treatments employ both immuno-suppressive and immuno-resolving strategies. This diagram contrasts conventional therapies (azathioprine, anti-TNF agents) with emerging PUFA-based approaches that promote active resolution of intestinal inflammation." />
  <figcaption>Figure 7. Current IBD treatments employ both immuno-suppressive and immuno-resolving strategies. This diagram contrasts conventional therapies (azathioprine, anti-TNF agents) with emerging PUFA-based approaches that promote active resolution of intestinal inflammation.<br>  Source: Eleonora Scaioli et al. "The Imbalance between n-6/n-3 Polyunsaturated Fatty Acids and Inflammatory Bowel." <em>International journal of molecular sciences</em>, 2017. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29206211/">29206211</a></figcaption>
</figure>

Related Evidence

C
Omega-3 Fatty Acids (EPA/DHA) for Ulcerative Colitis (UC)

Grade C · 8 studies

 C
Omega-3 Fatty Acids (EPA/DHA) for Crohn's Disease

Grade C · 6 studies